Skip to content
Search

Latest Stories

Bristol Labs director PM Raju succumbs to Covid-19

The co-founder and a senior director of Bristol Laboratories, one of the country’s leading ge­neric medicine manufacturers, died last Sunday (Feb 14) after con­tracting coronavirus.

PM Raju was admitted to the Royal Brompton Hospital in Lon­don last month after his condition deteriorated following the Covid-19 infection.


He succumbed to complica­tions from the virus, having been in the intensive care unit of the hospital for a month. He was 63 and is survived by his wife, Grace, his two sons, Hanson and Benson and his daughter-in-law, Jisha.

Raju helped found Bristol Lab­oratories and played a key role in its meteoric growth over the past decade. He was a close friend and associate of T Ramachandran, the founder and chairman and managing director of the company.

The two friends started the business from a small office in Harrow, North London in 1997 and together built an enterprise spanning the UK and Europe.

RAJU AND RAMACHANDRAN T Ramachandran (L) and PM Raju

Ramachandran said: “I can never forget 40 years of unconditional partnership with him being side by side with me and my family in happiness and sorrow.

“He was a brother to me and my wife Sreedevi and a beloved uncle to my daughters. Words will never do justice for the greatness of one soul who touched the lives of everyone he met.”

Both Raju and Ramachandran formed a close association while working for several years at IPCA Laboratories – a large pharmaceutical company based in India.

In 1997, Raju moved to the UK to help Ramachandran set up Bristol Laboratories and had since been overseeing all aspects of the company’s growth as “second in command”.

In a statement, Bristol Labora­tories said, “His passion, drive and loyalty towards the business was not just a professional one but a personal commitment to serve and excel in the field.

“He was a caring father, a pas­sionate leader and always a phone call away when you need­ed him. He never said no to any­one and has left a void in our hearts forever.”

Raju was a respected and pop­ular member of British pharma industry who did much to push innovation and develop new ter­ritories for Bristol Laboratories.

A regular presence at industry events, he built strong relation­ships with wholesalers and com­munity pharmacists who came to rely on Bristol Laboratories’ ex­tensive product portfolio.

Paying tribute, CEO of Sigma Pharma­ceuticals Bharat Shah said, “I have known Raju for more than 20 years. I have seen him trans­form from an export executive in India with IPCA to becoming a very powerful executive with Bristol Labs in the UK.

“He was instrumental in devel­oping Bristol Laboratories into one of the leading generic medicine manufacturers in the UK. He would help everyone in the most polite and effective manner. He will be greatly missed not only in the ge­nerics industry in the UK, but al­so by people who knew him.”

Born in Adoor, in India's southern state of Kerala, Raju completed his graduation in commerce from Kerala University.

He was the founder and a dedicated member of the Indian Orthodox Church in Hemel Hempstead, serving as the council member of the Diocese of UK-Europe and Africa for several years.

Diocesan Bishop Dr Mathews Mar Thimothios Metropolitan of the Indian Orthodox said: “He always stood as a pillar on my right side for all my missions of the diocese.

PM raju with Bishop PM Raju with bishop outside St Michael's Church in Hamworthy, Pool on Aug 31, 2019

Raju also played an important role in helping to establish a Malayalee Christian community in North London.

A religious leader who knew Raju described how he helped members of the community.

“When people (from Kerala) landed in the UK, whoever got in touch with him would always get plenty of help – anything from finding accommodation to finding a job. This has been the case for many years,” he said.

The secretary of the Hemel Hempstead church praised Raju as a “very hard working, soft spoken person and a great role model to everyone”.

More For You

Youth vaping : project to examine health impacts on children

Youth vaping : project to examine health impacts on children

Youth vaping: £62M research project to examine health impacts on children

The UK government has announced a £62 million research project to investigate the long-term health effects of vaping on young people, alongside wider influences on adolescent health and wellbeing.

While vaping is considered less harmful than smoking and can aid adult smokers in quitting, youth vaping has skyrocketed in recent years, with a quarter of 11 to 15-year-olds having tried it, the Department of Health and Social Care (DHSC) noted in a release.

Keep ReadingShow less
David Thomas Steps In as NPA’s New Wales Representative
Five NPA members are contesting for the remaining position in England (gettyimages)

NPA board update: David Thomas succeeds Raj Aggarwal OBE

Five NPA members are contesting for the remaining position in England

David Thomas, owner of LT Chemists in Newport, will replace Raj Aggarwal OBE as the next National Pharmacy Association (NPA) board member for Wales, following an uncontested election this month.

Following the conclusion of a nomination process last week, Baldev Bange, Aisling O’Brien, Sehar Shahid, and Sanjay Ganvir have been re-elected to the Board, representing areas of England and Scotland, according to a statement from NPA.

Keep ReadingShow less
Public Policy Projects calls for better use of community pharmacy skill mix to improve medicines adherence
Non-adherence to medicines remains a critical issue, with an estimated 30 to 50 per cent of medicines for long-term conditions not taken as prescribed. (gettyimages)

Leverage pharmacy skill mix to improve medicines adherence - report suggests

The report also suggested expanding the community pharmacy contractual framework to enable community pharmacy to deliver medicines reviews

Pharmacy technicians and assistants should be enabled to talk to patients about their medications to improve medicines adherence, a new report has recommended.

The report, How medicines optimisation contributes to population health, published recently by policy institute Public Policy Projects, highlighted that non-adherence to medicines remains a critical issue, with an estimated 30 to 50 per cent of medicines for long-term conditions not taken as prescribed.

Keep ReadingShow less
GHP calls for 10% mandated protected learning time for NHS pharmacists in new campaign
Many pharmacists end up doing ‘unpaid work’ to catch up with the required training (gettyimages)

Increase protected learning time for NHS pharmacists – GHP launches national campaign

Many pharmacists end up doing ‘unpaid work’ to catch up with the required training or completing self-learning in their own time.

The Guild of Healthcare Pharmacists (GHP) has launched a national campaign advocating for pharmacists working in the NHS to have a minimum of 10% of their contracted hours protected for supporting professional activities (SPA).

In a statement published on 7 February 2025, the GHP emphasised that this protected time “should be recognized by employers and embedded in job plans.”

Keep ReadingShow less
Pharmacy contract consultation to review medicine margin and reimbursement, says Kinnock

Pharmacy contract consultation to review medicine margin and reimbursement, says Kinnock

Kinnock confirms that an announcement on the 2025/26 GP contract would be made before April 2025

The 2025/26 pharmacy contract consultation will include a review of the medicine margin and reimbursement arrangements, health and care minister Stephen Kinnock has confirmed.

Kinnock made this statement in response to a written question from Nick Timothy, Conservative MP for West Suffolk, who asked the secretary of state for health and social care, if he will review the reimbursement system for pharmacies and GP practices dispensing medicines.

Keep ReadingShow less